EDX Medical Group PLC
Company Profile
Business description
EDX Medical Group PLC is principally engaged in the business of creating health testing solutions and developing biological and digital technologies to improve the detection of diseases and disorders. It develops and provides digital diagnostic products and services for testing in areas including cancer, cardiovascular disease, neurology, and infectious diseases. It operates a molecular biology and diagnostics laboratory in Cambridge, UK, from which it performs research & development and provides testing and genomic sequencing services. It has two operating segments: Medical goods and Medical services. The majority of revenue is generated from the Medical services segment. Geographically, all revenue was derived from the United Kingdom.
Contact
Milton Road
211 Cambridge Science Park
CambridgeCB4 0WA
GBRSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
15
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.70 | 60.30 | 0.69% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 68,309.46 | 647.26 | -0.94% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,682.10 | 67.70 | 0.79% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |